Literature DB >> 1458679

Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders.

S Loizou1, C Cofiner, A P Weetman, M J Walport.   

Abstract

The class and subclass distribution of an antibody response may give insight into the stimulating mechanism and likely effector functions. IgA, IgG and IgM anticardiolipin antibodies (aCL) were quantified in a consecutive series of 200 samples sent to an autoimmune serology laboratory to determine the relationships between aCL responses of each of these antibody classes and, in particular, whether there was any utility in the measurement of IgA aCL. Positive results for one of the three aCL isotypes were found in 105 samples (53%), and in 41 samples IgA aCL was detected (21%). However, amongst these unselected samples, little additional information was obtained by measurement of IgA aCL, which was found in conjunction with IgM or IgG aCL in all but five samples, and in these the isolated elevation of IgA aCL was only slight, and showed no disease specificity. The levels of each of the four IgG subclasses of aCL were measured in a subgroup of serum samples from 28 patients with autoimmune disease and from 29 patients with syphilis. Amongst the SLE patients IgG1 and IgG3 aCL were the predominant IgG subclasses, consistent with an antigen-driven, T cell-dependent antibody response. However, a subgroup of eight of the autoimmune subjects had predominant elevation of IgG2 aCL, possibly implying a role for T cell-independent antibody production to cardiolipin. Amongst the syphilis patients IgG1 and IgG3 aCL were also the predominant subclasses of aCL but IgG4 aCL were also detected in the majority of subjects, consistent with prolonged antigenic stimulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458679      PMCID: PMC1554592          DOI: 10.1111/j.1365-2249.1992.tb05864.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.

Authors:  D Alarcón-Segovia; M Delezé; C V Oria; J Sánchez-Guerrero; L Gómez-Pacheco; J Cabiedes; L Fernández; S Ponce de León
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

2.  IgG1 and IgG2 are the predominant subclasses of antiphospholipid antibody in women with the lupus anticoagulant.

Authors:  D Dostal-Johnson; N S Rote; D W Branch
Journal:  Clin Immunol Immunopathol       Date:  1990-02

Review 3.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

4.  Anticardiolipin antibodies in systemic lupus erythematous.

Authors:  N Snowden; P Wilson; R Pumphrey
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

5.  IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in systemic lupus erythematosus.

Authors:  A E Gharavi; E N Harris; M D Lockshin; G R Hughes; K B Elkon
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

6.  Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus.

Authors:  W H Leung; K L Wong; C P Lau; C K Wong; H W Liu
Journal:  Am J Med       Date:  1990-10       Impact factor: 4.965

7.  Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis.

Authors:  R A Levy; A E Gharavi; L R Sammaritano; L Habina; T Qamar; M D Lockshin
Journal:  J Rheumatol       Date:  1990-08       Impact factor: 4.666

8.  Severe Guillain-Barré syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients.

Authors:  G Frampton; J B Winer; J S Cameron; R A Hughes
Journal:  J Neuroimmunol       Date:  1988-08       Impact factor: 3.478

9.  Anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus.

Authors:  K Y Fong; S Loizou; M L Boey; M J Walport
Journal:  Br J Rheumatol       Date:  1992-07

10.  Relationship between antiphospholipid antibodies and recurrent fetal loss in patients with systemic lupus erythematosus and apparently healthy women.

Authors:  M Deleze; D Alarcón-Segovia; E Valdes-Macho; C V Oria; S Ponce de Leon
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

View more
  9 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 2.  Ethnic and geographical variation in antiphospholipid (Hughes) syndrome.

Authors:  I Uthman; M Khamashta
Journal:  Ann Rheum Dis       Date:  2005-05-26       Impact factor: 19.103

3.  Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  M Samarkos; K A Davies; C Gordon; S Loizou
Journal:  Clin Rheumatol       Date:  2005-08-10       Impact factor: 2.980

4.  Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype.

Authors:  G Lakos; E Kiss; N Regëczy; P Tarján; P Soltész; M Zeher; E Bodolay; S Szakony; S Sipka; G Szegedi
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

5.  IgG subclass serum levels in systemic lupus erythematosus patients.

Authors:  Gui-gao Lin; Jin-ming Li
Journal:  Clin Rheumatol       Date:  2009-07-12       Impact factor: 2.980

6.  High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P. vivax malaria.

Authors:  C A Facer; G Agiostratidou
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

8.  A human monoclonal IgA autoantibody--185/12--behaves like an autoimmune antiphospholipid antibody.

Authors:  I Yron; L Shohat; J Lahav; I P Witz; B Fisch
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 9.  Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Silvia Piantoni; Rossella Reggia; Francesca Dall'Ara; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.